云南省寄生虫病防治所
搜 索

OA登录

电子图书

云南南部恶性疟原虫对甲氟喹、奎宁、氨酚喹、氯喹、磺胺多辛/乙胺嘧及咯萘啶敏感性的体外测定

时间:2005-05-11

浏览量:2201

 

杨恒林  杨品芳  杨亚明     云南省疟疾防治研究所  思茅  665000

全文发表于《中国寄生虫学与寄生虫病杂志》1994122140-142

 

提要:19921012月在云南南部应用体外微量法测得甲氟喹、奎宁、氨酚喹、氯喹、磺胺多辛/乙胺嘧啶(磺/乙)及咯萘啶对恶性疟原虫的ID50依次为46480521502x 10425×10215nmolLID95分别为160153629268024×105/3×10560nmolL。恶性疟原虫对甲氟喹、奎宁均敏感;对氨酚喹及氯喹的抗生率分别为100%(3030)及96.7%(2930);咯萘啶测定5例,其中1例显示有抗生。20例中有的13例的恶性疟原虫可在最高药量磺/乙井中发育至裂殖体,提示当地恶性疟原虫对氯喹与氨酚有明显交叉抗性,对奎宁与甲氟喹可能有交叉抗性。

关键词:恶性疟原虫,体外微量法,甲氟喹,奎宁氨酚喹,氯喹,磺胺金辛,乙胺嘧啶,咯萘啶

 

IN VITRO SENSITIVITY OF PLASM ODIUM FALCIPARUM TO MEFLOQUINE, QUININE, AMODIAQUINE, CHLOROQUINE, PYRONARIDINE AND SULFADOXINE / PYRIMETIAMINE IN SOUTH YUNNAN

Yang Henglin, Yang Pinfang, Yang Yaming

Institute of Malaria prevention and Treatment of Yunnan Province, Simao  665000

 

ABSTRACT. The sensitivity of P. falciparum to mifloquine, quinine am odiaquine, chloroquine pyronaridine, and sulfadoxine / pyrimethamine (MEF, QNN, AMO, CHL ,PYR,S/P)was tested using in vitro microtest in south Yunnan Province in 1992. The ID50 were 46, 480, 52, 150, 2x 10425×102nmol/L, and 15nmol/L; respectively;ID95 were 160, 1 536, 292, 680, 24×105/3×105nmol/L 60nmol/L, respectively, All the isolates(30) were sensitive to MEF and QMN;100%(30/30) and 96.7%(29/30) isolates were found to be resistant to AMO and CHL, the cross-resis-tance rate was100% to the two drugs. One of 5 isolates exhibited resistance to PYR.The results suggest that the P. falciparum was susceptible to MEF and QNN,but was resistant to AMO,CHLand S/P.CHL-resistant P. faleiparum showed a marked cross-resistance to AMO, but not to MEF,QNN,and S/P; AMO-resistant P. falciparum exhibited cross-res is-tance to CHL, but not to MEF, QNN,and S/P.

Key words: Plasmodium falciparum, in vitro seisitivit, mefloquine, quinine, amodiaquine, chloroquine, sulfadoxine / pyrimethamine

 

:转载请注明出处、谢谢合作

 

联系电话

0879-2122152

云南省普洱市思茅区西园路6号

ADD:6 Xiyuan Road,Puer,Yunnan,P.R.China

版权所有 Copyright © 云南省寄生虫病防治所    滇ICP备05004264号-3 滇公网安备 53080202000356号

技术支持:川海科技

本站部分素材源于网络,如有侵权,请联系作者删除!

健康咨询

合作交流

科研工作

返回顶部